What is Leerink Partnrs' Forecast for Pharvaris Q2 Earnings?

Pharvaris (NASDAQ:PHVS - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Pharvaris in a report released on Wednesday, June 4th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.89) for the quarter, down from their prior forecast of ($0.87). The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris' Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.90) EPS, FY2025 earnings at ($3.66) EPS and FY2026 earnings at ($3.33) EPS.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09).

PHVS has been the topic of a number of other reports. Cantor Fitzgerald lowered their target price on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Wedbush reissued an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a research report on Thursday.

Pharvaris Stock Up 4.5%

NASDAQ:PHVS opened at $16.78 on Monday. The stock's 50 day moving average price is $15.56 and its 200 day moving average price is $17.02. The company has a market capitalization of $877.43 million, a PE ratio of -5.99 and a beta of -2.86. Pharvaris has a 52-week low of $11.51 and a 52-week high of $25.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its position in Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after buying an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris in the fourth quarter valued at about $64,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Pharvaris in the fourth quarter valued at about $111,000. Point72 Asset Management L.P. purchased a new stake in shares of Pharvaris in the fourth quarter valued at about $152,000. Finally, Legal & General Group Plc boosted its holdings in shares of Pharvaris by 11.2% in the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after acquiring an additional 994 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.